2023-03-30 07:02:00 ET
- Trevena press release ( NASDAQ: TRVN ): Q4 GAAP EPS of -$0.73 beats by $1.01 .
- Cash and cash equivalents were $38.3M as of December 31, 2022, which the company believes will be sufficient to fund its operating expenses and capital expenditure requirements into the fourth quarter of 2023.
- “We are excited to report initial topline data from the OLINVYK real-world outcomes studies, VOLITION and ARTEMIS. The GI and cognitive results build upon the extensive data set for OLINVYK, and we look forward to reporting respiratory outcome data as soon as it is available,” said Carrie Bourdow, President and CEO of Trevena. “We are also pleased to now have two proof-of-concept studies underway for TRV045, and we expect to report top-line data later this year.”
For further details see:
Trevena GAAP EPS of -$0.73 beats by $1.01